Promising lead molecules identified in the Hit-to-Lead step, that had already have acceptable PK properties and demonstrated hint of efficacy in-vivo, are further optimized to a preclinical candidate suitable for clinical assessment in human patients.
In order that a successful lead optimization is achieved, the following parameters are measured/tested in an effort that adds on to the already existing Lead criteria.
Some highlights of Aragen-IDD’s lead optimization infrastructure –
Digital workplace options (InCoRe platform)
Solutions offered via the DMTA process in a lively, transparent, interactive and collaborative work model. This enables efficient SAR of the optimized lead series, scientific strategy and priotized solutions during the process of Lead Optimization.
Data generation
In vitro and mechanistic assay data can support compound prioritisation for in vivo PK and efficacy studies.
Innovation & Expertise
Integrating wealth of scientific expertise from experienced scientists with the use of ML- & AI-generated models based on Aragen’s proprietary internal fingerprints database generated from literature and vendor databases to deliver innovative solutions.
Track record
Aragen has delivered high-quality clinical candidates for our collaborators and partners over the last decade.
Route development, Formulation expertise & Scale-up
Aragen’s Chemical development expertise together with the Formulation team provides large-scale APIs for studies in GLP or non-GLP safety assessment batches. Both chemical development and formulation team are integrated in the lead optimisation stage to identify early and robust process chemistry solutions before nomination of development candidate. Chemical development and formulation teams may support early process and formulation considerations before development candidate nomination.
